Format

Send to

Choose Destination
Curr Rheumatol Rep. 2010 Feb;12(1):34-9. doi: 10.1007/s11926-009-0081-6.

The current state of biomarkers in systemic sclerosis.

Author information

1
Division of Rheumatology, Johns Hopkins Scleroderma Center, Johns Hopkins University, 5501 Hopkins Bayview Circle, Baltimore, MD 21224, USA. lhummers@jhmi.edu

Abstract

Scleroderma is a complex, multisystem autoimmune rheumatic disease with wide heterogeneity in phenotype and outcome. There are often coexisting ongoing pathologic processes including immune system activation, progressive fibrosis, and vascular disease in subsets of patients. Currently, it is challenging to identify patients at risk for developing adverse outcomes and to determine which patients are responding to current therapies. For these reasons, it is highly valuable to find easily measurable biomarkers that may represent ongoing disease activity or treatment response. This review examines the current state of biomarker development in systemic sclerosis and identifies areas in which further work should be directed.

PMID:
20425531
PMCID:
PMC3329274
DOI:
10.1007/s11926-009-0081-6
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center